Edition:
United States

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

1.17USD
26 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.17
Open
$1.17
Day's High
$1.19
Day's Low
$1.14
Volume
23,712
Avg. Vol
108,131
52-wk High
$6.13
52-wk Low
$0.82

Latest Key Developments (Source: Significant Developments)

Marinus Pharmaceuticals provides business update and reports Q1 results
Monday, 1 May 2017 07:30am EDT 

May 1 (Reuters) - Marinus Pharmaceuticals Inc -:Marinus Pharmaceuticals provides business update and reports first quarter 2017 financial results.Marinus Pharmaceuticals - believes that cash, cash equivalents and investments, as of march 31, 2017, are adequate to fund operations into h2 of 2018.  Full Article

Marinus Pharma signs supply agreement with Cydex Pharma
Thursday, 6 Apr 2017 04:35pm EDT 

Cydex Pharmaceuticals Inc : Marinus Pharmaceuticals Inc - on march 31, 2017, entered into a license agreement and a supply agreement with Cydex Pharmaceuticals Inc - sec filing . Marinus Pharmaceuticals Inc-under terms of supply agreement, co required to purchase all of requirements for Captisol with respect to Ganaxolone from Cydex . Marinus Pharmaceuticals Inc- Cydex granted co exclusive license to use Cydex Captisol drug formulation system, related intellectual property . Marinus Pharmaceuticals Inc-under terms of supply agreement, Cydex is required to supply co with Captisol for such purposes, subject to certain limitations . Marinus Pharmaceuticals Inc-as consideration for license,co paid upfront fee, required to make additional payments on achievement of specified milestones .Marinus Pharmaceuticals Inc- will be required to pay royalties to Cydex on sales of Ganaxolone in low-to-mid single digits based on levels of annual net sales.  Full Article

Marinus Pharmaceuticals provides business update and 2016 financial results
Monday, 13 Mar 2017 07:30am EDT 

Marinus Pharmaceuticals Inc : Marinus pharmaceuticals provides business update and 2016 financial results . Marinus pharmaceuticals - December 31, 2016, company had cash, cash equivalents and investments of $30.1 million, compared to $57.7 million as of December 31, 2015 .Believe cash, cash equivalents and investments as of Dec 31,will enable us to fund requirements into second half of 2018.  Full Article

Marinus announces positive preliminary data from children with CDKl5 genetic disorder
Monday, 23 Jan 2017 07:30am EST 

Marinus Pharmaceuticals Inc : Marinus announces positive preliminary data from children with cdkl5 genetic disorder . Marinus announces positive preliminary data from children with cdkl5 genetic disorder .Marinus pharmaceuticals inc- enrollment is continuing in study with top-line data expected in mid-2017.  Full Article

Marinus Pharma net loss per share $0.46
Tuesday, 9 Aug 2016 04:15pm EDT 

Marinus Pharmaceuticals Inc : Marinus pharmaceuticals provides business update and reports second quarter 2016 financial results .Qtrly net loss per share of common stock-basic and diluted $0.46.  Full Article

Sphera Global Healthcare Management LP reports 6 pct passive stake in Marinus Pharmaceuticals
Wednesday, 6 Jul 2016 11:29am EDT 

Marinus Pharmaceuticals Inc : Sphera Global Healthcare Management LP reports 6 pct passive stake in Marinus Pharmaceuticals as of June 28, 2016 - SEC Filing Source - http://bit.ly/29i2Nxy Further company coverage: [MRNS.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Marinus Pharmaceuticals says Ganaxolone did not meet primary endpoint
Monday, 13 Jun 2016 07:30am EDT 

Marinus Pharmaceuticals Inc : Ganaxolone did not meet primary endpoint . Ganaxolone was generally safe and well tolerated . Marinus plans to discontinue its program in adult focal onset seizures . Plans to focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications. . Most common adverse events (>5%) reported at greater rates than placebo were somnolence (23.5% versus 4.5%), dizziness and fatigue . Majority of adverse events were rated as mild in severity .Announces Top-Line results from phase 3 trial in adult focal onset seizures.  Full Article

Marinus Pharmaceuticals, Inc announces pricing of common stock
Friday, 6 Nov 2015 09:08am EST 

Marinus Pharmaceuticals, Inc:Announces pricing of public offering of common stock.Says public offering of 5 million common shares priced at $6.00 per share.  Full Article

Marinus Pharmaceuticals announces public offering of common stock
Thursday, 5 Nov 2015 04:01pm EST 

Marinus Pharmaceuticals Inc:Intends to offer and sell shares of its common stock in an underwritten public offering.Intends to use the net proceeds of this offering to advance the preclinical and clinical development of ganaxolone.  Full Article

Marinus Pharmaceuticals Inc announces positive end-of-phase 2 meeting with FDA for ganaxolone in focal onset seizures
Wednesday, 9 Sep 2015 07:00am EDT 

Marinus Pharmaceuticals Inc:Says completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA).Says the objective of the meeting was to obtain FDA feedback on the nonclinical and clinical programs to support registration of ganaxolone for the adjunctive treatment of focal onset seizures in adults.Says top-line data from the study are anticipated in Q1 2016.  Full Article

More From Around the Web

BRIEF-Marinus Pharmaceuticals provides business update and reports Q1 results

* Marinus Pharmaceuticals provides business update and reports first quarter 2017 financial results